Haplotype analysis of the apolipoprotein A5 gene in obese pediatric patients

International Journal of Pediatric Obesity

Volumn 6, Issue 2 -2, 2011, Pages

  Horvatovich, Katalin ^a   Bokor, Szilvia ^a   Baráth, Ákos ^b   Maász, Anita ^a   Kisfali, Péter ^a   Járomi, Luca ^a   Polgár, Noémi ^a   Tóth, Dénes ^a   Répásy, Judit ^a   Endreffy, Emoke ^b   Molnár, Dénes ^a   Melegh, Béla ^a  

^a UNIVERSITY OF PÉCS   (Hungary)

^b UNIVERSITY OF SZEGED   (Hungary)

Author keywords

APOA5; Haplotypes; Metabolic syndrome; Pediatric obesity; Serum triglycerides

Indexed keywords

APOLIPOPROTEIN A5; CHOLESTEROL; TRIACYLGLYCEROL;

ADOLESCENT; ALLELE; ARTICLE; CHILDHOOD DISEASE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; OBESITY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM; TRIACYLGLYCEROL BLOOD LEVEL;

ADOLESCENT; APOLIPOPROTEINS A; BIOLOGICAL MARKERS; BODY MASS INDEX; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; CHOLESTEROL; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HAPLOTYPES; HUMANS; HUNGARY; LOGISTIC MODELS; MALE; OBESITY; ODDS RATIO; PHENOTYPE; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK ASSESSMENT; RISK FACTORS; TRIGLYCERIDES;

EID: 79960023633     PISSN: 17477166     EISSN: 17477174     Source Type: Journal    
DOI: 10.3109/17477166.2010.490268     Document Type: Article

References (45)

1. Holst-Schumacher I, Nunez-Rivas H, Monge-Rojas R et al. Components of the metabolic syndrome among a sample of overweight and obese Costa Rican schoolchildren. Food Nutr Bull. 2009;30(2):161-70.
2. Cameron AJ, Shaw JE, Zimmet PZ. The metabolic syndrome: prevalence in worldwide populations. Endocrinol Metab Clin North Am. 2004;33(2):351-75. (Pubitemid 38680634)
3. Gomez M, Ramirez M, Disdier O. Prevalence of the metabolic syndrome among a determined Puerto Rican population. P R Health Sci J. 2006;25(2):111-6.
4. Berenson GS, Srinivasan SR. Cholesterol as a risk factor for early atherosclerosis: the Bogasula Heart Study. N. Engl. J. Med. 1998;338:1650-6.
5. Bokor S, Frelut ML, Vania A et al. Prevalence of metabolic syndrome in European obese children. Int J Pediatr Obes. 2008;3 Suppl 2:3-8.
6. Zimmet P, Alberti G, Kaufman F et al. The metabolic syndrome in children and adolescents. Lancet. 2007; 369 (9579): 2059-61. (Pubitemid 46935928)
7. Brambilla P, Lissau I, Flodmark CE et al. Metabolic riskfactor clustering estimation in children: to draw a line across pediatric metabolic syndrome. Int J Obes (Lond). 2007; 31(4):591-600. (Pubitemid 46482362)
8. Pennacchio LA, Olivier M, Hubacek JA et al. An apolipoprotein infl uencing triglycerides in humans and mice revealed by comparative sequencing. Science. 2001;294 (5540):169-73. (Pubitemid 32952971)
9. Aouizerat BE, Kulkarni M, Heilbron D et al. Genetic analysis of a polymorphism in the human apoA-V gene: effect on plasma lipids. J Lipid Res. 2003;44(6):1167-73. (Pubitemid 37279634)
10. Pennacchio LA, Olivier M, Hubacek JA et al. Two independent apolipoprotein A5 haplotypes infl uence human plasma triglyceride levels. Hum Mol Genet. 2002;11(24):3031-8. (Pubitemid 35414816)
11. Havasi V, Szolnoki Z, Talian G et al. Apolipoprotein A5 gene promoter region T-1131C polymorphism associates with elevated circulating triglyceride levels and confers susceptibility for development of ischemic stroke. J Mol Neurosci. 2006;29(2):177-83. (Pubitemid 44352541)
12. Szalai C, Keszei M, Duba J et al. Polymorphism in the promoter region of the apolipoprotein A5 gene is associated with an increased susceptibility for coronary artery disease. Atherosclerosis. 2004;173(1):109-14. (Pubitemid 38224202)
13. Yamada Y, Kato K, Hibino T et al. Prediction of genetic risk for metabolic syndrome. Atherosclerosis. 2007;191(2): 298-304. (Pubitemid 46400713)
14. Moreno-Luna R, Perez-Jimenez F, Marin C et al. Two independent apolipoprotein A5 haplotypes modulate postprandial lipoprotein metabolism in a healthy Caucasian population. J Clin Endocrinol Metab. 2007;92(6):2280-5. (Pubitemid 46997134)
15. K isfali P, Mohas M, Maasz A et al. Haplotype analysis of the apolipoprotein A5 gene in patients with metabolic syndrome. Nutr Metab Cardiovasc Dis. 2009 Aug 17. [Epub ahead of print].
16. Endo K, Yanagi H, Araki J et al. Association found between the promoter region polymorphism in the apolipoprotein A-V gene and the serum triglyceride level in Japanese schoolchildren. Hum Genet. 2002;111(6):570-2. (Pubitemid 36075090)
17. Cole TJ, Bellizzi MC, Flegal KM et al. Establishing a standard defi nition for child overweight and obesity worldwide: international survey. BMJ. 2000;320(7244):1240-3. (Pubitemid 30240471)
18. Elosua R, Ordovas JM, Cupples LA et al. Variants at the APOA5 locus, association with carotid atherosclerosis, and modifi cation by obesity: the Framingham Study. J Lipid Res. 2006;47(5):990-6. (Pubitemid 43764695)
19. Chen ES, Furuya TK, Mazzotti DR et al. APOA1/A5 Variants and Haplotypes as a Risk Factor for Obesity and Better Lipid Profi les in a Brazilian Elderly Cohort. Lipids. 2010; 45(6):511-7.
20. Meigs JB, Rutter MK, Sullivan LM et al. Impact of insulin resistance on risk of type 2 diabetes and cardiovascular disease in people with metabolic syndrome. Diabetes Care. 2007;30(5):1219-25. (Pubitemid 46684651)
21. Moreno LA, Pineda I, Rodriguez G et al. Waist circumference for the screening of the metabolic syndrome in children. Acta Paediatr. 2002;91(12):1307-12. (Pubitemid 36174054)
22. Bloom SR, Kuhajda FP, Laher I et al. The obesity epidemic: pharmacological challenges. Mol Interv. 2008;8(2):82-98.
23. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet. 2005;365(9468):1415-28. (Pubitemid 40523737)
24. Freedman DS, Dietz WH, Srinivasan SR et al. The relation of overweight to cardiovascular risk factors among children and adolescents: the Bogalusa Heart Study. Pediatrics. 1999; 103(6 Pt 1):1175-82. (Pubitemid 29258789)
25. Molnar D. The prevalence of the metabolic syndrome and type 2 diabetes mellitus in children and adolescents. Int J Obes Relat Metab Disord. 2004;28 Suppl 3:S70 - 4. (Pubitemid 39564321)
26. Vanhala M, Vanhala P, Kumpusalo E et al. Relation between obesity from childhood to adulthood and the metabolic syndrome: population based study. BMJ. 1998;317 (7154):319. (Pubitemid 28353826)
27. Barkai L, Paragh G. [Metabolic syndrome in childhood and adolescence]. Orv Hetil. 2006;147(6):243-50. (Pubitemid 47470386)
28. Cullen P. Evidence that triglycerides are an independent coronary heart disease risk factor. Am J Cardiol. 2000;86(9): 943-9.
29. v an der Vliet HN, Sammels MG, Leegwater AC et al. Apolipoprotein A-V: a novel apolipoprotein associated with an early phase of liver regeneration. J Biol Chem. 2001;276(48): 44512-20.
30. Grallert H, Sedlmeier EM, Huth C et al. APOA5 variants and metabolic syndrome in Caucasians. J Lipid Res. 2007; 48(12):2614-21. (Pubitemid 350272846)
31. Kisfali P, Mohas M, Maasz A et al. Apolipoprotein A5 IVS3- 476A allelic variant associates with increased trigliceride levels and confers risk for development of metabolic syndrome in Hungarians. Circ J. 2008;72(1):40-3. (Pubitemid 351413324)
32. Maasz A, Kisfali P, Horvatovich K et al. Apolipoprotein A5 T-1131C variant confers risk for metabolic syndrome. Pathol Oncol Res. 2007;13(3):243-7. (Pubitemid 350221227)
33. Aristimuno GG, Foster TA, Voors AW et al. Infl uence of persistent obesity in children on cardiovascular risk factors: the Bogalusa Heart Study. Circulation. 1984;69(5):895-904. (Pubitemid 14137285)
34. Weiss R, Dziura J, Burgert TS et al. Obesity and the metabolic syndrome in children and adolescents. N Engl J Med. 2004;350(23):2362-74. (Pubitemid 38702847)
35. Martinelli N, Trabetti E, Bassi A et al. The -1131 T> C and S19W APOA5 gene polymorphisms are associated with high levels of triglycerides and apolipoprotein C-III, but not with coronary artery disease: an angiographic study. Atherosclerosis. 2007;191(2):409-17. (Pubitemid 46400704)
36. Dorfmeister B, Zeng WW, Dichlberger A et al. Effects of six APOA5 variants, identifi ed in patients with severe hypertriglyceridemia, on in vitro lipoprotein lipase activity and receptor binding. Arterioscler Thromb Vasc Biol. 2008;28(10): 1866-71.
37. Merkel M, Heeren J. Give me A5 for lipoprotein hydrolysis! J Clin Invest. 2005;115(10):2694-6.
38. van der Vleuten GM, Isaacs A, Zeng WW et al. Haplotype analyses of the APOA5 gene in patients with familial combined hyperlipidemia. Biochim Biophys Acta. 2007;1772(1): 81-8. (Pubitemid 46001720)
39. Olivier M, Wang X, Cole R et al. Haplotype analysis of the apolipoprotein gene cluster on human chromosome 11. Genomics. 2004;83(5):912-23. (Pubitemid 38469930)
40. Talmud PJ, Hawe E, Martin S et al. Relative contribution of variation within the APOC3/A4/A5 gene cluster in determining plasma triglycerides. Hum Mol Genet. 2002;11(24): 3039-46. (Pubitemid 35414817)
41. Wright WT, Young IS, Nicholls DP et al. SNPs at the APOA5 gene account for the strong association with hypertriglyceridaemia at the APOA5/A4/C3/A1 locus on chromosome 11q23 in the Northern Irish population. Atherosclerosis. 2006;185(2):353-60.
42. Ruiz-Narvaez EA, Yang Y, Nakanishi Y et al. APOC3/A5 haplotypes, lipid levels, and risk of myocardial infarction in the Central Valley of Costa Rica. J Lipid Res. 2005;46(12):2605-13. (Pubitemid 43107472)
43. Waterworth DM, Jansen H, Nicaud V et al. Interaction between insulin (VNTR) and hepatic lipase (LIPC-514C> T) variants on the response to an oral glucose tolerance test in the EARSII group of young healthy men. Biochim Biophys Acta. 2005;1740(3):375-81. (Pubitemid 40804750)
44. Li WW, Dammerman MM, Smith JD et al. Common genetic variation in the promoter of the human apo CIII gene abolishes regulation by insulin and may contribute to hypertriglyceridemia. J Clin Invest. 1995;96(6):2601-5.
45. Travers SH, Jeffers BW, Eckel RH. Insulin resistance during puberty and future fat accumulation. J Clin Endocrinol Metab. 2002;87(8):3814-8. (Pubitemid 34879532)